The Prenatal Health sale simplifies the business and provides $210M cash to strengthen the balance sheet, but the core Cancer Care Continuum and Mental Health revenue grew only 1% combined YoY. Monitor the close of the Labcorp transaction and any updates on Medicare coverage for Precise MRD, which could be a catalyst for 2027 growth.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $6.29entry
- T+1 · 11d ago −5.88%α −6.19% · $5.92
- T+5 · 5d ago −9.70%α −12.99% · $5.68
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Myriad Genetics reported Q3 2026 revenue of $202.7M, above the $191.3M consensus, but GAAP net loss widened to $43.9M ($0.46 per share) from $27.4M a year ago. The company raised the mid-point of its full-year 2026 revenue guidance to $780M-$790M and announced a definitive agreement to sell its Prenatal Health business to Labcorp for $210M in cash, expected to close by early 2027.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $202.7M, up 6% sequentially but down 1% YoY, above the $191.3M consensus
- GAAP net loss $43.9M ($0.46 per share) vs $27.4M loss a year ago; adjusted loss per share $0.11
- Full-year 2026 revenue guidance raised to $780M-$790M (mid-point raised from $870M prior range, reflecting the Prenatal divestiture)
- Definitive agreement to sell Prenatal Health business to Labcorp for $210M cash plus inventory value, expected to close by early 2027
- Cancer Care Continuum revenue $123.9M, up 1% YoY; Mental Health revenue $39.5M, up 2% YoY; Prenatal Health revenue $39.3M, down 12% YoY
- Cash and cash equivalents $107.1M at quarter end; adjusted free cash flow positive $1.6M in Q3
Financial Impact
Revenue beat consensus by $11.4M (6.0%); Prenatal sale valued at $210M cash, roughly 38% of market cap
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Cancer Care Continuum | $123.9M | +1.1% |
| Mental Health | $39.5M | +2.1% |
| Prenatal Health | $39.3M | -11.7% |
Risk Factors
- Prenatal Health sale may not close on expected timeline or at all, subject to regulatory approvals
- Core revenue growth remains low single-digit; GAAP losses continue to widen
- Adjusted gross margin declined 200 bps YoY to 67.9%, reflecting lower volumes and investment costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-070135 |
| Document: mygn-20261104.htm | 0001628280-26-070135 |
| Document: 0001628280-26-070135-index-headers.html | 0001628280-26-070135 |
| Document: 0001628280-26-070135-index.html | 0001628280-26-070135 |
| Document: 0001628280-26-070135.txt | 0001628280-26-070135 |
| 8-K Data (Synthetic) | 0001628280-26-070135 |
Track record
16 reports on MYGN
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+5 after the Oct 20, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $5.57 Now $5.57 −0.00% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $5.67 to $5.72 Now $5.57 −1.76% ▲ +0.88% −0.44% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 Viewing Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $6.02 to $6.29 Now $5.57 −7.48% ▲ +4.49% +8.89% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $6.63 to $6.67 Now $5.57 −15.99% ▲ +0.60% +0.99% vs SPY
- Oct 20, 202627d ago 8-K Bullish 7/10 Entry $5.54 to $5.57 Now $5.57 +0.54% ▲ +0.54% +0.02% vs SPY
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $3.98 Now $5.57 +39.95% No price data
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $4.20 to $4.08 Now $5.57 +32.62% ▼ −2.86% −2.85% vs SPY
- Sep 16, 20268w ago 8-K Neutral 3/10 Entry $3.86 to $4.14 Now $5.57 +44.30% ▲ +7.25% +6.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers